Affordable Access

Errata

Publisher
American Diabetes Association
Publication Date
Volume
31
Issue
8
Identifiers
DOI: 10.2337/dc08-er08b
Source
Legacy
Keywords
  • Errata
Disciplines
  • Medicine

Abstract

Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE, for the Sitagliptin 036 Study Group: Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 30:1979–1987, 2007 In Table 2 of the article above, an asterisk was missing denoting a significant difference between the 1,000 mg metformin b.i.d. group and placebo. The corrected table appears on the following page. The online version reflects these changes. Table 2 Efficacy end points following a meal tolerance test Parameter Placebo Sitagliptin 100 mg q.d. Metformin 500 mg b.i.d. Metformin 1,000 mg b.i.d. Sitagliptin 50 mg + metformin 500 mg b.i.d. Sitagliptin 50 mg + metformin 1,000 mg b.i.d. 2-h PPG (mg/dl)     n 129 136 141 138 147 152     Baseline 276.8 ± 66.7 285.4 ± 82.8 292.7 ± 74.6 283.4 ± 81.8 291.8 ± 84.6 286.9 ± 76.2     Week 24 281.3 ± 88.2 233.8 ± 89.5 236.3 ± 70.8 207.0 ± 69.4 196.3 ± 72.5 170.3 ± 58.6     Change from baseline 0.3 (−10.4 to 11.0) −51.9 (−62.3 to −41.5) −53.4 (−63.6 to −43.2) −78.0 (−88.3 to −67.6) −92.5 (−102.6 to −82.5) −116.6 (−126.4 to −106.7)

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments
F